Srinivas K. Tantravahi,
MBBS, MRCP(UK)
Languages Spoken: English
Dr. Tantravahi has received his medical degree from Guntur medical college, India. He then completed Internal Medicine residency and Hematology and Oncology fellowship training at University of Utah Hospital. His clinical interests include multiple myeloma, stem cell transplantation, and myeloproliferative neoplasm. Research interests are targeted therapy in CML and myeloproliferative neoplasms.
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor (Clinical) |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) Medical Council of India |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.8/ 5
Care provider's explanation of condition/problem
4.7/ 5
Care provider's effort to include me in decisions
4.8/ 5
Wait time at clinic
4.3/ 5
Care provider's concern for questions & worries
4.8/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
October 03, 2022
HUNTSMAN CANCER CENTER
Yes , since I started this big deal I received the best care ! Thanks
UofU Patient
October 03, 2022
HUNTSMAN CANCER CENTER
My Dr. Is amazing. It is because of his effort that I am alive today. My Dr. Is Trantivahie.
UofU Patient
September 11, 2022
SUGAR HOUSE HEALTH CENTER
Wonderful experience
UofU Patient
September 10, 2022
HUNTSMAN CANCER CENTER
Dr. Tantravahi is very kind and shows concern for me as a patient. I would absolutely recommend him and his practice to others. Definitely 1 of the Best.
UofU Patient
August 03, 2022
HUNTSMAN CANCER CENTER
Dr Tantravahi is very knowledgeable, courteous, an excellent listener and provides thoughtful and clear explanations and recommendations based on the current data, for treatment. I highly recommend him.
UofU Patient
July 31, 2022
SUGAR HOUSE HEALTH CENTER
Dr. Tantravahi explained everything easily and showed concern for me during my appointment. His bedside manner was great.
UofU Patient
July 30, 2022
HUNTSMAN CANCER CENTER
Tantravahi is very good. He is a worthy successor of Deininger.
UofU Patient
July 18, 2022
HUNTSMAN CANCER CENTER
Very pleased
UofU Patient
July 17, 2022
HUNTSMAN CANCER CENTER
Incredible experience with Dr. Tantravahie. Amazing doctor!
UofU Patient
July 11, 2022
SUGAR HOUSE HEALTH CENTER
The Doctor was thorough and reassuring, excellent! I did not feel rushed and he answered all my questions.
UofU Patient
July 02, 2022
HUNTSMAN CANCER CENTER
If Dr. T were a poker hand, he'd be 5 aces.
UofU Patient
June 21, 2022
SUGAR HOUSE HEALTH CENTER
The Doctor made me laugh and that the best medicine.
UofU Patient
May 29, 2022
HUNTSMAN CANCER CENTER
Dr. TANTRAVAHI IS EXCEPTIONAL!
UofU Patient
May 07, 2022
HUNTSMAN CANCER CENTER
I have nothing but good to say
UofU Patient
May 06, 2022
HUNTSMAN CANCER CENTER
Good experience.
UofU Patient
April 13, 2022
HUNTSMAN CANCER CENTER
My primary doctor was wonderful. The Resident who saw me first, however, was dismissive of my concerns, used euphemistic language to trivialize test results, and did not seem interested in really listening to me. I would prefer to not see her again.
UofU Patient
March 26, 2022
HUNTSMAN CANCER CENTER
Dr. Tantravahi, his fellows and staff are always attentive, thorough, and very professional, while, at the same time, friendly.
UofU Patient
March 21, 2022
HUNTSMAN CANCER CENTER
Dr. Trinivasan is the best I could wish to treat me. He provides context and reassurance.
UofU Patient
February 16, 2022
SUGAR HOUSE HEALTH CENTER
Dr. Tantravahi provided excellent care. He spent time listening to my concerns and answering all of my questions. He was very pleasant and made me feel that he was genuinely interested in ensuring that I understood the medical issues related to my visit and future lab tests.
UofU Patient
January 18, 2022
SUGAR HOUSE HEALTH CENTER
Good
UofU Patient
January 16, 2022
SUGAR HOUSE HEALTH CENTER
Always a great experience from start to finish.
UofU Patient
December 31, 2021
HUNTSMAN CANCER CENTER
Satisfied with my Dr.
UofU Patient
November 16, 2021
SUGAR HOUSE HEALTH CENTER
Dr. Tantravahi treated me with respect and included me in the decision making of my care. He is an outstanding doctor.
UofU Patient
November 15, 2021
HUNTSMAN CANCER CENTER
I felt like I was interrupting something and really didn't seem to be the focus of the doctor during my visit.
UofU Patient
October 24, 2021
SUGAR HOUSE HEALTH CENTER
He was very kind in person, but in his notes very dismissive of my other severe, non-hematological conditions. I felt gaslighted and misunderstood.
UofU Patient
October 11, 2021
HUNTSMAN CANCER CENTER
Very good experience.
UofU Patient
October 03, 2021
HUNTSMAN CANCER CENTER
Dr T makes me feel so much better re my health concerns. Like speaking to a family member. Dr T is super GREAT!
UofU Patient
October 03, 2021
SUGAR HOUSE HEALTH CENTER
I was hesitant to answer this survey when It first popped up because I felt like the doctor T from the very beginning he stated that this issue wasn't or shouldn't be something of his concern. He mentioned a few times it was the other 2 doctors that should be trying to ..diagnos??? My issues. I was let down and felt uneasy while there. He ordered labs even though. After I left I thought if he didn't think this was his..department? He shouldn't have taken any lab work. I am/was looking for answers to find "why" or "reason" I was referred to this specialist The visit wasn't productive I thought.
UofU Patient
September 20, 2021
HUNTSMAN CANCER CENTER
I can't think of his name Dr. T, but he was taking over for Dr. Patel who is on maternity leave. I felt that the minute he walked in the room, he had made up his mind on what the plan was and I was so confused when I left that I didn't do anything with that plan and won't until Dr. Patel comes back and I can talk with her about it. What Dr. T said compared to what his nurse said before she went to get him were two completely different things. I felt with him, I didn't really have a decision. I am still confused.
UofU Patient
September 13, 2021
HUNTSMAN CANCER CENTER
Dr. Tantrivahi was concerned about my having to take antacids that can have an adverse effect on my medication, and wrote me a prescription for an antacid to be taken only once per day.
UofU Patient
August 12, 2021
SUGAR HOUSE HEALTH CENTER
I appreciated the answers to my questions.
UofU Patient
July 22, 2021
HUNTSMAN CANCER CENTER
Dr. Tantrivahi listened to my concerns and answered my questions to my satisfaction.
UofU Patient
July 06, 2021
SUGAR HOUSE HEALTH CENTER
Good
UofU Patient
May 24, 2021
HUNTSMAN CANCER CENTER
Dr. T explained his concerns regarding my treatment as well as explained everything to my satisfaction.
UofU Patient
May 13, 2021
HUNTSMAN CANCER CENTER
Again, staff was well informed, attentive and willing to take my input for consideration. just took awhile to get in to see them.
UofU Patient
April 06, 2021
HUNTSMAN CANCER CENTER
great experienc
UofU Patient
March 07, 2021
SUGAR HOUSE HEALTH CENTER
All Excellent
UofU Patient
February 28, 2021
HUNTSMAN CANCER CENTER
Explanations of all aspects of my condition, and treatment, were clear and easy to understand.
UofU Patient
February 26, 2021
SUGAR HOUSE HEALTH CENTER
I feel extremely pesky, I don't mean to be, but I know I am not an easy patient. Dr. Tantravahi is VERY patient with me. I certainly trust his expertise and appreciate his willingness to explain hematological health with me. I also appreciate him listening to my concern about a possible genetic blood issue, Thalassemia, even though he may not directly agree with my personal perspective, seeing as he is a very knowledgable Hematologist and certainly would know better than I do, he still listened. Dr. Tantravahi is willing to accept we are all human, even himself, and this lends to his compassion and willingness to listen and help. I hope he knows I think very highly of him, I understand that I am a very inquisitive person which can be pesky or annoying, but he always takes the time to talk about the medical science behind my blood panels. I appreciate his knowledge and compassion and patience.
UofU Patient
February 26, 2021
SUGAR HOUSE HEALTH CENTER
everything was good
UofU Patient
February 06, 2021
HUNTSMAN CANCER CENTER
Dr. Tantravahi and the entire staff were exemplary!
UofU Patient
January 04, 2021
HUNTSMAN CANCER CENTER
My provider was very attentive, nice, and great at explaining options depending on results. I was very pleased.
UofU Patient
December 21, 2020
HUNTSMAN CANCER CENTER
I liked his professional yet relaxed demeanor.
UofU Patient
December 20, 2020
HUNTSMAN CANCER CENTER
Physician was informed, patient centered and caring.
Dr. Tantravahi has received his medical degree from Guntur medical college, India. He then completed Internal Medicine residency and Hematology and Oncology fellowship training at University of Utah Hospital. His clinical interests include multiple myeloma, stem cell transplantation, and myeloproliferative neoplasm. Research interests are targeted therapy in CML and myeloproliferative neoplasms.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor (Clinical) |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) Medical Council of India |
Education History
| Fellowship | University of Utah Advanced Hematology & Oncology Fellow, 2015 |
| Fellowship | University of Utah Hematology & Oncology Fellow, 2014 |
| Residency | University of Utah Internal Medicine Resident, 2011 |
| Residency | Barnsley District General Hospital Internal Medicine Senior House Officer, 2008 |
| Residency | Sheffield Teaching Hospitals Internal Medicine Senior House Officer, 2007 |
| Residency | Rotherham District General Hospital Internal Medicine Senior House Officer, 2006 |
| Residency | Macclesfield District General Hospital Internal Medicine Senior House Officer, 2005 |
| Residency | George Elliot Hospital Internal Medicine Senior House Officer, 2004 |
| Professional Medical | Guntur Medical College Medicine M.B.B.S., 2003 |
Selected Publications - Journal Articles
Journal Article
- Pemmaraju N, Garcia JS, Potluri J, Harb JG, Sun Y, Jung P, Qin QQ, Tantravahi SK, Verstovsek S, Harrison C (2022). Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol, 9(6), e434-e444.
- Li P, Venkatachalam S, Ospina Cordona D, Wilson L, Kovacsovics T, Moser KA, Miles RR, Beck DB, George T, Tantravahi SK (2021). A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm. Blood Adv, 6(2), 405-409.
- Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Coulter DW, Diamond E, Flagg A, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Janku F, Karmali R, Morgan D, Raldow AC, Stefanovic A, Tantravahi SK, Walkovich K, Zhang L, Bergman MA, Darlow SD (2021). Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(11), 1277-1303.
- Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz JM, Borate U, Wilmot B, Tognon CE, Bock AM, Pollyea DA, Radhakrishnan SM, Radhakrishnan S, Patel PA, Collins RH, Tantravahi SK, Deininger MW, Fan G, Druker BJ, Shinde U, Tyner JW, Press RD, McWeeney SK, Agarwal A (2021). Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult AML patients. Blood, 139, 1208-1221.
- Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, OHare T, Deininger MW (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991.
- Kim K, McMillin GA, Bernard PS, Tantravahi S, Walker BS, Schmidt RL (2019). Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia. PLoS One, 14(12), e0226552.
- Willis C, Menon J, Unni S, Au T, Yoo M, Biskupiak J, Brixner D, Ndife B, Joseph G, Bonifacio G, Stein E, Tantravahi S, Shami PJ, Kovacsovics T, Stenehjem D (2019). Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center. Leuk Res, 87, 106262.
- Franzini A, Pomicter AD, Yan D, Khorashad JS, Tantravahi SK, Than H, Ahmann JM, OHare T, Deininger MW (2019). The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood Adv, 3(20), 2949-2961.
- Walker BS, Schmidt RL, Tantravahi S, Kim K, Hanson KE (2019). Cost-effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic stem cell transplant. Transpl Infect Dis, 21(5), e13148.
- Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, OHare T, Deininger MW (2018). Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Clin Cancer Res, 25(7), 2323-2335.
- Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal N (2016). Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clin Genitourin Cancer, 14(2), 153-9.
- Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, OHare T, Deininger MW (2016). Age-related mutations and chronic myelomonocytic leukemia. Leukemia, 30(4), 906-13.
- Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD, Agarwal N (2015). Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clin Genitourin Cancer, 13(3), e131-7.
- Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, OHare T, Deininger MW (2015). shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood, 125(11), 1772-81.
- Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, OHare T, Gunning PT, Deininger MW (2015). Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia, 29(3), 586-597.
- Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, Stenehjem DD, Agarwal N (2015). Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. J Oncol, 2015, 181926.
Book Chapter
- Tantravahi SK, Kovacsovics T (2015). Myeloma. In Randall RL (Ed.), Metastatic Bone Disease: An Integrated Approach to Patient Care (2016 Edition, pp. 83-102). New York: Springer.
- Kollepara SLS, Tantravahi SK, Batten J, Agarwal N (2014). Integrating emerging science into clinical practice: Targeting androgen signaling in Castration Resistant Metastatic Prostate Cancer. In Srivastava R, Maksymowicz W, Lopaczynski W (Eds.), Lost in Translation: Barriers in Incentives for Translational Research. Singapore: World Scientific Publishing Company.
- Tantravahi SK, Khorashad JS, Deininger MW (In Press). Genomic Landscape of myeloproliferative neoplasms. In Oxford Hand Book of Hematology.
Letter
- Tantravahi SK, Huber BD, Vagher J, Maese L, Pomicter AD, Al-Sweel N, Asch JD, Toydemir RM, Hong B, Parker C (2022). Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia. [Letter to the editor]. Br J Haematol, 198(6), e78-e81.
- Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Krger N, Luetkens T (2019). In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. [Letter to the editor]. Leukemia, 34(1), 317-321.
- Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger MW (2016). A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. [Letter to the editor]. Leuk Lymphoma, 57(10), 2441-4.
Global Impact
Education History
| Residency | Barnsley District General Hospital Internal Medicine Senior House Officer |
| Residency | Sheffield Teaching Hospitals Internal Medicine Senior House Officer |
| Residency | Rotherham District General Hospital Internal Medicine Senior House Officer |
| Residency | Macclesfield District General Hospital Internal Medicine Senior House Officer |
| Residency | George Elliot Hospital Internal Medicine Senior House Officer |
| Professional Medical | Guntur Medical College Medicine M.B.B.S. |